New Gaba-containing analogues of human growth hormone releasing hormone (1-30)-amide: II. Detailed in vivo biological examinations

M. Kovacs, I. Mezo, I. Teplan, M. Hollósi, J. Kajtar, B. Flerko

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Analogues of human growth hormone-releasing hormone-(1-30)-amide [GH-RH(1-30)amide] were tested for their ability to stimulate GH release in vivo by injecting the peptides intravenously (iv), subcutaneously (sc), and intramuscularly (im). The analogues involved derivatization with Nle27 and Gaba substituents at the C-terminus with or without D-amino acid(s) in the peptide chain. The potency of the analogues was compared to that of GH-RH(1-29)-amid testing their ability to release GH at 5, 15 and 30 min after the administration. In iv test the potency of the analogues was 1.2-2 times higher than that of the GH-RH(1-29)amide, and no significant differences were detected between the potencies of the analogues with or without D-amino acid. In the sc test the analogue with D-Ala2, Nle27, and Gaba30 substitutions expressed 8.0-51.7 times higher potency than the GH-RH(1-29)-amide, however, the analogue with similar modifications but with L-Ala2 showed the same low potency (1.2-2.1) as in the iv test. Results from the im experiments were similar to those of SC test. The most potent analogues were those which had D-Ala2, Nle27, and Gaba30 substitutions with Gly15 or Leu15. Circular dichroism (CD) spectra of the analogues showed that Leu in position 15 increased the stability of the predominant α-helix conformation, which improved the absorption of the molecule. The introduction of D-Arg11 into the D-Ala2, Leu15, Nle27 Gaba30 GH-RH(1-30)-amide molecule decreased the sc and im potencies, without altering the iv activities. Our data indicate that in vivo GH-releasing potency of the GH-RH(1-30)amide analogues highly depends on the route of administration, and that D-amino acid(s) are responsible for the increased sc and im potency. Parenteral absorption of the analogue appears to be related to its α-helical conformation.

Original languageEnglish
Pages (from-to)799-805
Number of pages7
JournalJournal of Endocrinological Investigation
Volume16
Issue number10
Publication statusPublished - 1993

Fingerprint

Growth Hormone-Releasing Hormone
Human Growth Hormone
Amides
Amino Acids
Peptides
Circular Dichroism

Keywords

  • CD spectra
  • GH release
  • GH-RH
  • GH-RH analogues
  • In vivo assay

ASJC Scopus subject areas

  • Endocrinology

Cite this

New Gaba-containing analogues of human growth hormone releasing hormone (1-30)-amide : II. Detailed in vivo biological examinations. / Kovacs, M.; Mezo, I.; Teplan, I.; Hollósi, M.; Kajtar, J.; Flerko, B.

In: Journal of Endocrinological Investigation, Vol. 16, No. 10, 1993, p. 799-805.

Research output: Contribution to journalArticle

@article{a82330cba8a84e459d971ac0297eeba1,
title = "New Gaba-containing analogues of human growth hormone releasing hormone (1-30)-amide: II. Detailed in vivo biological examinations",
abstract = "Analogues of human growth hormone-releasing hormone-(1-30)-amide [GH-RH(1-30)amide] were tested for their ability to stimulate GH release in vivo by injecting the peptides intravenously (iv), subcutaneously (sc), and intramuscularly (im). The analogues involved derivatization with Nle27 and Gaba substituents at the C-terminus with or without D-amino acid(s) in the peptide chain. The potency of the analogues was compared to that of GH-RH(1-29)-amid testing their ability to release GH at 5, 15 and 30 min after the administration. In iv test the potency of the analogues was 1.2-2 times higher than that of the GH-RH(1-29)amide, and no significant differences were detected between the potencies of the analogues with or without D-amino acid. In the sc test the analogue with D-Ala2, Nle27, and Gaba30 substitutions expressed 8.0-51.7 times higher potency than the GH-RH(1-29)-amide, however, the analogue with similar modifications but with L-Ala2 showed the same low potency (1.2-2.1) as in the iv test. Results from the im experiments were similar to those of SC test. The most potent analogues were those which had D-Ala2, Nle27, and Gaba30 substitutions with Gly15 or Leu15. Circular dichroism (CD) spectra of the analogues showed that Leu in position 15 increased the stability of the predominant α-helix conformation, which improved the absorption of the molecule. The introduction of D-Arg11 into the D-Ala2, Leu15, Nle27 Gaba30 GH-RH(1-30)-amide molecule decreased the sc and im potencies, without altering the iv activities. Our data indicate that in vivo GH-releasing potency of the GH-RH(1-30)amide analogues highly depends on the route of administration, and that D-amino acid(s) are responsible for the increased sc and im potency. Parenteral absorption of the analogue appears to be related to its α-helical conformation.",
keywords = "CD spectra, GH release, GH-RH, GH-RH analogues, In vivo assay",
author = "M. Kovacs and I. Mezo and I. Teplan and M. Holl{\'o}si and J. Kajtar and B. Flerko",
year = "1993",
language = "English",
volume = "16",
pages = "799--805",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Editrice Kurtis s.r.l.",
number = "10",

}

TY - JOUR

T1 - New Gaba-containing analogues of human growth hormone releasing hormone (1-30)-amide

T2 - II. Detailed in vivo biological examinations

AU - Kovacs, M.

AU - Mezo, I.

AU - Teplan, I.

AU - Hollósi, M.

AU - Kajtar, J.

AU - Flerko, B.

PY - 1993

Y1 - 1993

N2 - Analogues of human growth hormone-releasing hormone-(1-30)-amide [GH-RH(1-30)amide] were tested for their ability to stimulate GH release in vivo by injecting the peptides intravenously (iv), subcutaneously (sc), and intramuscularly (im). The analogues involved derivatization with Nle27 and Gaba substituents at the C-terminus with or without D-amino acid(s) in the peptide chain. The potency of the analogues was compared to that of GH-RH(1-29)-amid testing their ability to release GH at 5, 15 and 30 min after the administration. In iv test the potency of the analogues was 1.2-2 times higher than that of the GH-RH(1-29)amide, and no significant differences were detected between the potencies of the analogues with or without D-amino acid. In the sc test the analogue with D-Ala2, Nle27, and Gaba30 substitutions expressed 8.0-51.7 times higher potency than the GH-RH(1-29)-amide, however, the analogue with similar modifications but with L-Ala2 showed the same low potency (1.2-2.1) as in the iv test. Results from the im experiments were similar to those of SC test. The most potent analogues were those which had D-Ala2, Nle27, and Gaba30 substitutions with Gly15 or Leu15. Circular dichroism (CD) spectra of the analogues showed that Leu in position 15 increased the stability of the predominant α-helix conformation, which improved the absorption of the molecule. The introduction of D-Arg11 into the D-Ala2, Leu15, Nle27 Gaba30 GH-RH(1-30)-amide molecule decreased the sc and im potencies, without altering the iv activities. Our data indicate that in vivo GH-releasing potency of the GH-RH(1-30)amide analogues highly depends on the route of administration, and that D-amino acid(s) are responsible for the increased sc and im potency. Parenteral absorption of the analogue appears to be related to its α-helical conformation.

AB - Analogues of human growth hormone-releasing hormone-(1-30)-amide [GH-RH(1-30)amide] were tested for their ability to stimulate GH release in vivo by injecting the peptides intravenously (iv), subcutaneously (sc), and intramuscularly (im). The analogues involved derivatization with Nle27 and Gaba substituents at the C-terminus with or without D-amino acid(s) in the peptide chain. The potency of the analogues was compared to that of GH-RH(1-29)-amid testing their ability to release GH at 5, 15 and 30 min after the administration. In iv test the potency of the analogues was 1.2-2 times higher than that of the GH-RH(1-29)amide, and no significant differences were detected between the potencies of the analogues with or without D-amino acid. In the sc test the analogue with D-Ala2, Nle27, and Gaba30 substitutions expressed 8.0-51.7 times higher potency than the GH-RH(1-29)-amide, however, the analogue with similar modifications but with L-Ala2 showed the same low potency (1.2-2.1) as in the iv test. Results from the im experiments were similar to those of SC test. The most potent analogues were those which had D-Ala2, Nle27, and Gaba30 substitutions with Gly15 or Leu15. Circular dichroism (CD) spectra of the analogues showed that Leu in position 15 increased the stability of the predominant α-helix conformation, which improved the absorption of the molecule. The introduction of D-Arg11 into the D-Ala2, Leu15, Nle27 Gaba30 GH-RH(1-30)-amide molecule decreased the sc and im potencies, without altering the iv activities. Our data indicate that in vivo GH-releasing potency of the GH-RH(1-30)amide analogues highly depends on the route of administration, and that D-amino acid(s) are responsible for the increased sc and im potency. Parenteral absorption of the analogue appears to be related to its α-helical conformation.

KW - CD spectra

KW - GH release

KW - GH-RH

KW - GH-RH analogues

KW - In vivo assay

UR - http://www.scopus.com/inward/record.url?scp=0027746027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027746027&partnerID=8YFLogxK

M3 - Article

C2 - 8144854

AN - SCOPUS:0027746027

VL - 16

SP - 799

EP - 805

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 10

ER -